Treatment of Schamberg's disease with pentoxifylline - therapeutic trial
DOI:
https://doi.org/10.66344/jpad.v18i2.574Keywords:
pentoxifylline, Schamberg’s diseaseAbstract
Thirty patients with Schamberg's disease were started on pentoxifylline (400 mg three times daily) for a period of 9 weeks. Improvement was assessed at 3 weekly intervals by two observers independently and graded as mild (<25%), moderate (25-50%) and marked (>50%). Marked improvement was observed in 15/30 (50%) patients. We conclude that pentoxifylline should be considered as first line therapy in all patients with Schamberg's disease.
References
1. Champion RH. Purpura. In: Champion RH, Burton JL, Burns DA, Breathnach SM, eds. Textbook of Dermatology, Vol III, 6th edn. London: Blackwell Scientific Publications; 1998. p. 2149-2151.
2. Kano Y, Hiroyama K, Shiohra T Successful treatment of Schamberg's disease with pentoxifylline. J Am Acad Dermatol 1997; 36: 827-30.
3. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994; 30: 603-621.
4. Ely H. Is pentoxifylline the drug of the decade? J Am Acad Dermatol 1994; 30: 603-40.
5. Schwarz A, Arragne Y, Simson M et al. Pentoxifylline suppresses UVB induced cutokine release by keratinocytes (abstract). J Invest Dermatol 1993; 101: 388.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Rostami Mogaddam Majid
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
